SCHEMBL5889595

SCHEMBL5889595

CCOCn1c(C(=O)NCCN)cc2cc(N(C(=O)c3ccc4[nH]c(C(=O)N(c5ccc6c(c5)cc(C(=O)NCCN)n6COCC)c5ccc6c(c5)cc(C(=O)NCCN)n6COCC)cc4c3)c3ccc4c(c3)cc(C(=O)NCCN)n4COCC)ccc21

nearest known ligand 0.36

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.36
MMP13 P45452 1/20 0.36
ITGB3 P05106 14/20 0.35
ITGA2B P08514 14/20 0.35
HRH3 Q9Y5N1 1/20 0.34
CNR1 P21554 2/20 0.34
HRAS P01112 1/20 0.34
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5889597 0.95 HRH3 (0.41) MMP2MMP13ITGB3ITGA2BHRH3
SCHEMBL5889838 0.92 ITGB3 (0.36) ITGB3ITGA2BCNR1HRASESR1
SCHEMBL5889840 0.87 HRH3 (0.38) ITGB3ITGA2BHRH3HRASESR1
SCHEMBL6500906 0.83 ITGB3 (0.37) ITGB3ITGA2BHRH3HRASESR1
SCHEMBL6500730 0.74 HRAS (0.44) ITGB3ITGA2BHRASESR1ESR2
SCHEMBL5889555 0.71 HRAS (0.47) ITGB3ITGA2BHRASESR1ESR2
SCHEMBL5889686 0.69 HRAS (0.45) ITGB3ITGA2BHRASESR1ESR2
SCHEMBL5889571 0.62 HRAS (0.59) ITGB3ITGA2BHRASESR1ESR2
SCHEMBL26490132 0.62 KDM4E (0.56) ITGB3ITGA2BHRH3CNR1KDM4E
SCHEMBL5679912 0.62 MMP13 (0.62) MMP2MMP13ITGB3ITGA2BHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064218-B2 Aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity GENELABS TECHNOLOGIES, INC. (US) 2006-06-20 US disclosed
US-6906103-B2 Compounds possessing antibacterial, antifungal or antitumor activity GENELABS TECHNOLOGIES, INC. (US) 2005-06-14 US disclosed
US-20030212113-A1 Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity GLAXOSMITHKLINE LLC 2003-11-13 US disclosed
WO-2003057212-A1 POLYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY GENELABS TECHNOLOGIES, INC. (US) 2003-07-17 WO disclosed
US-20030119749-A1 Novel compounds possessing antibacterial, antifungal or antitumor activity SMITHKLINE BEECHAM CORPORATION 2003-06-26 US disclosed
EP-1294713-A2 COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY GENELABS TECHNOLOGIES, INC. (US) 2003-03-26 EP disclosed
WO-2002000650-A2 NOVEL COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY GENELABS TECHNOLOGIES, INC. (US) 2002-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119749-A1 Novel compounds possessing antibacterial, antifungal or antitumor activity CYP51A1, MCL1, ERG28 MMP2 928/4885MMP13 1826/4885ITGB3 4164/4885
US-20030212113-A1 Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity TYR, CYP51A1, ODC1 MMP2 1498/4885MMP13 3203/4885ITGB3 4485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.